Art. -Nr.: HY-12364

C75

52 Cited Publications

Kundenbewertung

Based on 52 publication(s) in Google Scholar

C75 is a synthetic fatty-acid synthase (FASN) inhibitor; inhibits prostate cancer cells PC3 with an IC₅₀ of 35 μM. C75 is a potent CPT1A activator.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.91%
CAS. Nr.: 218137-86-1
Formel: C₁₄H₂₂O₄
Molecular Weight:254.32

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

C75 Chemical Structure

CAS. Nr.: 218137-86-1

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (52)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

C75 is a synthetic fatty-acid synthase (FASN) inhibitor; inhibits prostate cancer cells PC3 with an IC₅₀ of 35 μM^[1]^[2]^[3]. C75 is a potent CPT1A activator^[5].

IC₅₀ & Target

CPT-1A

Cellular Effect

Cell Line	Type	Value	Description	References
Fibroblast	IC₅₀	63.2 μM Compound: (+/-)-C-75	Antiproliferative activity against fibroblasts (unknown origin) after 72 hrs by MTT assay Antiproliferative activity against fibroblasts (unknown origin) after 72 hrs by MTT assay	[PMID: 28324785]
HCT-116	IC₅₀	46.4 μM Compound: (+/-)-C-75	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 28324785]
HepG2	IC₅₀	7.4 ng/mL Compound: C75	Inhibition of fatty acid synthase type 1 in human HepG2 cells assessed as [1-14C]acetate incorporation into cellular fatty acid Inhibition of fatty acid synthase type 1 in human HepG2 cells assessed as [1-14C]acetate incorporation into cellular fatty acid	[PMID: 18805004]
Huh-7	CC₅₀	>100 μM Compound: 68	Cytotoxicity against human HuH7 cells assessed as cell viability after 48 hrs by CellTiter Glo assay Cytotoxicity against human HuH7 cells assessed as cell viability after 48 hrs by CellTiter Glo assay	[PMID: 26771861]
MCF7	IC₅₀	27.3 μM Compound: (+/-)-C-75	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 28324785]
MDA-MB-231	IC₅₀	43.8 μM Compound: (+/-)-C-75	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 28324785]
MIA PaCa-2	IC₅₀	21.8 μM Compound: (+/-)-C-75	Antiproliferative activity against human MIAPaCa2 cells after 72 hrs by MTT assay Antiproliferative activity against human MIAPaCa2 cells after 72 hrs by MTT assay	[PMID: 28324785]
OVCAR-3	IC₅₀	21.9 μM Compound: (+/-)-C-75	Antiproliferative activity against human OVCAR3 cells after 72 hrs by MTT assay Antiproliferative activity against human OVCAR3 cells after 72 hrs by MTT assay	[PMID: 28324785]
PC-3	IC₅₀	26.8 μM Compound: (+/-)-C-75	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	[PMID: 28324785]
SK-BR-3	IC₅₀	19.8 μM Compound: (+/-)-C-75	Antiproliferative activity against human SKBR3 cells after 72 hrs by MTT assay Antiproliferative activity against human SKBR3 cells after 72 hrs by MTT assay	[PMID: 28324785]

In Vitro

C75 inhibits PC3 cell growht with an IC₅₀ of 35 μM at 24 h. C75 (10-50 μM) also reduces the growth of LNCaP spheroids in a concentration-dependent manner with an IC₅₀ of 50 μM^[1]. (-)-C75 inhibits FAS activity and has a cytotoxic effect on tumor cell lines, without affecting food consumption. (+)-C75 inhibits CPT1 and its administration produces anorexia, suggesting that central inhibition of CPT1 is essential for the anorectic effect of C75. The differential activity of C75 enantiomers may lead to the development of potential new specific drugs for cancer and obesity^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

C75 blocks fasting-induced c-Fos expression in the arcuate nucleus (Arc), lateral hypothalamic area (LHA), and paraventricular nucleus (PVN) 10–24 h after i.p. injection. Intraperitoneal administration of C75 at 30 mg/kg body weight inhibits food intake of mice by ≥95% within 2 h after i.p. injection^[3]. C75-treated DIO mice has a 50% greater weight loss, and a 32.9% increased production of energy because of fatty acid oxidation. C75 treatment of rodent adipocytes and hepatocytes and human breast cancer cells increases fatty acid oxidation and ATP levels by increasing CPT-1 activity, even in the presence of elevated concentrations of malonyl-CoA^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 218137-86-1
Appearance Solid
Molecular Weight 254.32
Formel C₁₄H₂₂O₄
Color White to off-white
SMILES

O=C(C(C1=C)C(CCCCCCCC)OC1=O)O
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (52)

All WBCell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

Vertical RAS pathway inhibition in pancreatic cancer drives therapeutically exploitable mitochondrial alterations. [Abstract]

2026 Jan 16;11(1):33. PMID: 41545339
Nature

Tumour extracellular vesicles and particles induce liver metabolic dysfunction. [Abstract]

2023 Jun;618(7964):374-382. PMID: 37225988
J Hepatol

ARRB1 inhibits non-alcoholic steatohepatitis progression by promoting GDF15 maturation. [Abstract]

2020 May;72(5):976-989. PMID: 31857195
Cell Metab

Metabolic-Pathway-Based Subtyping of Triple-Negative Breast Cancer Reveals Potential Therapeutic Targets. [Abstract]

2021 Jan 5;33(1):51-64.e9. PMID: 33181091
Nat Genet

Alterations in PD-L1 succinylation shape anti-tumor immune responses in melanoma. [Abstract]

2025 Mar;57(3):680-693. PMID: 40069506
Gastroenterology

Oncogenic Fatty Acid Metabolism Rewires Energy Supply Chain in Gastric Carcinogenesis. [Abstract]

2024 Jan 24:S0016-5085(24)00064-7. PMID: 38272100
Bioact Mater

Exosomes derived from impaired liver aggravate alveolar bone loss via shuttle of Fasn in type 2 diabetes mellitus. [Abstract]

2023 Nov 9:33:85-99. PMID: 38024229
Nat Commun

The UFL1-AKT positive feedback loop promotes breast cancer progression by enhancing lipid synthesis. [Abstract]

2026 Jan 20;17(1):614. PMID: 41559041
Nat Commun

Lipid droplets sequester palmitic acid to disrupt endothelial ciliation and exacerbate atherosclerosis in male mice. [Abstract]

2024 Sep 27;15(1):8273. PMID: 39333556
Autophagy

FASN mediates crosstalk between autophagy and lipid metabolism via the AMPK-MTOR pathway in early age-related macular degeneration. [Abstract]

2026 May 18:1-20. PMID: 42152481
Adv Sci (Weinh)

Extracellular Vesicle-Transferred ATP-Citrate Lyase Induces Monocyte Differentiation Toward Tumor-Associated Macrophages and Fuels Hepatocellular Carcinoma Progression. [Abstract]

2026 Jun;13(35):e21458. PMID: 41995119
Cell Rep Med

A CD36-dependent non-canonical lipid metabolism program promotes immune escape and resistance to hypomethylating agent therapy in AML. [Abstract]

2024 May 29:101592. PMID: 38843841
J Immunother Cancer

PI3Kα inhibitor CYH33 triggers antitumor immunity in murine breast cancer by activating CD8+T cells and promoting fatty acid metabolism. [Abstract]

2021 Aug;9(8):e003093. PMID: 34373258
Cell Mol Biol Lett

CLDN6 inhibits breast cancer growth and metastasis through SREBP1-mediated RAS palmitoylation. [Abstract]

2024 Aug 21;29(1):112. PMID: 39169280
J Neuroinflammation

Glyceryl triacetate promotes blood-brain barrier recovery after ischemic stroke through lipogenesis-mediated IL-33 in mice. [Abstract]

2023 Nov 15;20(1):264. PMID: 37968698
Cell Death Dis

Fatty acid synthase-mediated lipid droplet formation enhances macrophage killing of Staphylococcus aureus. [Abstract]

2025 Oct 7;16(1):715. PMID: 41057302
Cell Death Dis

Metformin alleviates inflammation through suppressing FASN-dependent palmitoylation of Akt. [Abstract]

2021 Oct 12;12(10):934. PMID: 34642298
Cell Death Dis

SIK2 enhances synthesis of fatty acid and cholesterol in ovarian cancer cells and tumor growth through PI3K/Akt signaling pathway. [Abstract]

2020 Jan 13;11(1):25. PMID: 31932581
Regen Biomater

Matrix stiffness boosts PDAC chemoresistance via SCD1-dependent lipid metabolic reprogramming. [Abstract]

2025 Jun 16:12:rbaf056. PMID: 40741620
Cell Death Discov

Oncoprotein CYB561, acting in IRE1-XBP1-SREBF1 and FAK-ERK pathway, promotes breast cancer lipogenesis and progression. [Abstract]

2026 Apr 13;12(1):227. PMID: 41974658
Cell Death Discov

The interplay of transcriptional coregulator NUPR1 with SREBP1 promotes hepatocellular carcinoma progression via upregulation of lipogenesis. [Abstract]

2022 Oct 28;8(1):431. PMID: 36307402

C75 purchased from MedChemExpress. Usage Cited in: Cell Death Discov. 2022 Oct 28;8(1):431. [Abstract]

Cell Counting Kit-8 (CCK8) assay. NUPR1 overexpression-induced proliferation of MHCC-97H and SK-Hep1 cells can be reversed by C75 (50 μM; 48 h).

C75 purchased from MedChemExpress. Usage Cited in: Cell Death Discov. 2022 Oct 28;8(1):431. [Abstract]

Transwell migration assay. C75 reduces the migration ability of NUPR1-overexpressing SK-Hep1 cells.
Cell Rep

Targeting ZDHHC12-mediated PARP1 palmitoylation potentiates PARP inhibitor cytotoxicity. [Abstract]

2026 Jan 24;45(2):116910. PMID: 41581148
Cell Rep

Oxidized mC modulates synthetic lethality to PARP inhibitors for the treatment of leukemia. [Abstract]

2023 Jan 31;42(1):112027. PMID: 36848231
Cell Rep

The ApoA-I mimetic peptide 5A enhances remyelination by promoting clearance and degradation of myelin debris. [Abstract]

2022 Nov 8;41(6):111591. PMID: 36351388
Anal Chem

Molecular Imaging and In Situ Quantitative Profiling of Fatty Acid Synthase with a Chemical Probe. [Abstract]

2020 Mar 17;92(6):4419-4426. PMID: 32053360
Mol Metab

Long-chain acyl-CoA synthetase-4 regulates endometrial decidualization through a fatty acid β-oxidation pathway rather than lipid droplet accumulation. [Abstract]

2024 Jun:84:101953. PMID: 38710444
Ecotoxicol Environ Saf

Integrating network toxicology and experimental validation to elucidate the molecular mechanism basis of chondrotoxicity of Benzo[a]pyrene in osteoarthritis. [Abstract]

2026 May:316:120177. PMID: 42034589
Hepatol Int

Small extracellular vesicles derived from lipotoxic hepatocytes transport FASN to promote hepatic stellate cell activation. [Abstract]

2025 Nov 12. PMID: 41225085
J Ethnopharmacol

Paris polyphylla Smith var. yunnanensis-derived saponins potentiate the antitumor activity of GPX4 inhibitors. [Abstract]

2026 Feb 28:357:120890. PMID: 41232632
Respir Res

Inhibition of fatty acid synthase protects obese mice from acute lung injury via ameliorating lung endothelial dysfunction. [Abstract]

2023 Mar 15;24(1):81. PMID: 36922854
PLoS Pathog

The impact of fatty acid synthase on HSV-1 infection dynamics. [Abstract]

2025 May 6;21(5):e1013068. PMID: 40327680
Pharmaceuticals (Basel)

New UB006 Derivatives With Higher Solubility and Cytotoxic Activity in Ovarian Cancer Cells. [Abstract]

2025 Jan 31;18(2):194. PMID: 40006009
Cancers (Basel)

Liver X Receptor Ligand GAC0001E5 Downregulates Antioxidant Capacity and ERBB2/HER2 Expression in HER2-Positive Breast Cancer Cells. [Abstract]

2024 Apr 25;16(9):1651. PMID: 38730603
Mol Neurobiol

Ox-LDL Induces Neuron Apoptosis and Worsens Neurological Outcomes in aSAH via Fas/FADD Pathway. [Abstract]

2025 Apr 8. PMID: 40199806
Lipids Health Dis

Dysregulated lipid metabolism is associated with kidney allograft fibrosis. [Abstract]

2024 Feb 3;23(1):37. PMID: 38308271
Biochim Biophys Acta Mol Basis Dis

Integrated application of transcriptome and metabolomics reveals potential therapeutic targets for the polarization of atherosclerotic macrophages. [Abstract]

2022 Dec 1;1868(12):166550. PMID: 36150660
Aquaculture

2026 May 7;623:744131.
J Virol

Pvf/Pvr signaling relieves white spot syndrome virus-induced lipid consumption to inhibit viral infection in shrimp. [Abstract]

2026 Apr 29:e0018226. PMID: 42053404
Eur J Immunol

Hyperinflammation by Human Macrophages Induced by SARS-CoV-2 Anti-Spike IgG Is Dependent on Glucose and Fatty Acid Metabolism. [Abstract]

2025 Dec;55(12):e70087. PMID: 41416928
Eur J Immunol

Anti-SARS-CoV-2 Spike IgA2 Induces Inflammation by Human Macrophages. [Abstract]

2025 Oct;55(10):e70068. PMID: 41054024
J Cell Sci

Redox-dependent AMPK inactivation disrupts metabolic adaptation to glucose starvation in xCT-overexpressing cancer cells. [Abstract]

2022 Aug 1;135(15):jcs259090. PMID: 35775474
Vet Res

Mechanistic role of lipid metabolism in foot-and-mouth disease virus (FMDV) replication. [Abstract]

2026 May 9;57(1):72. PMID: 42106845
Food Chem Toxicol

Apoptosis induction in human prostate cancer cells related to the fatty acid metabolism by wogonin-mediated regulation of the AKT-SREBP1-FASN signaling network. [Abstract]

2022 Nov:169:113450. PMID: 36208653
Am J Physiol Gastrointest Liver Physiol

Low-dose galactose rebalances HBP-mTORC1-SREBP-1c signaling to suppress hepatic lipogenesis and protect against early-stage alcohol-related liver disease. [Abstract]

2026 Feb 1;330(2):G170-G188. PMID: 41528029
Mol Immunol

High fat diet promotes asthma by inhibiting the differentiation of regulatory T cells via E3 ubiquitin ligase ITCH. [Abstract]

2026 Apr:192:32-44. PMID: 41791173
Am J Cancer Res

Angiopoietin-like 4 deficiency upregulates macrophage function through the dysregulation of cell-intrinsic fatty acid metabolism. [Abstract]

2020 Feb 1;10(2):595-609. PMID: 32195030

C75 purchased from MedChemExpress. Usage Cited in: Am J Cancer Res. 2020 Feb 1;10(2):595-609. [Abstract]

Of the transcription of spliced X-box-binding protein 1 (sXBP1) and phosphorylated translational initiation factor 2 in eukaryotes (eIF2α) are higher in ANGTPL4-/- macrophages but are restored to normal levels following C75 treatment.
Vet Microbiol

25-hydroxycholesterol inhibits classical swine fever virus entry into porcine alveolar macrophages by depleting plasma membrane cholesterol. [Abstract]

2023 Mar:278:109668. PMID: 36709687
Anticancer Drugs

Thrombospondin-2 induces M2 macrophage polarization through fatty acid metabolism to drive lung adenocarcinoma proliferation. [Abstract]

2025 Jul 1;36(6):459-467. PMID: 40053399
bioRxiv

2026 Feb 1.
SSRN

2025 Dec 23.
bioRxiv

2025 February 08.
SSRN

2023 May 24.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (393.21 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.9321 mL

19.6603 mL

39.3205 mL

5 mM

0.7864 mL

3.9321 mL

7.8641 mL

10 mM

0.3932 mL

1.9660 mL

3.9321 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (9.83 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (9.83 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (9.83 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Protocol 4

Add each solvent one by one: 5% DMSO 40% PEG300 5% Tween-80 50% Saline

Solubility: ≥ 1.25 mg/mL (4.92 mM); Clear solution

Protocol 5

Add each solvent one by one: 5% DMSO 95% (20% SBE-β-CD in Saline)

Solubility: ≥ 1.25 mg/mL (4.92 mM); Clear solution

Protocol 6

Add each solvent one by one: 5% DMSO 95% Corn Oil

Solubility: ≥ 1.25 mg/mL (4.92 mM); Clear solution

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Cell Assay^[1]

Cells are seeded in 96-well plates and incubated for 2 days to allow exponential phase growth. Cells are then ished twice with PBS and treated with C75. After 24 or 48 h incubation, MTT is added to a final concentration of 0.5 mg/ml and cultures are incubated for 2 h. Cells are then solubilized with DMSO before measuring absorbance at 570 nm. Cell growth is also measured, using MTT assay, every 24 h up to 96 h^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[3]

Mice: C75 is administered either by i.p. (i.p.; 30 mg/kg of body weight) or i.c.v. (10 μg in 3 μL of RPMI medium 1640) injection. One, 11.5, and 24 h after i.p. injection, cumulative food intake is measured, mice are killed, brains are sectioned, and slices are subjected to immunohistochemical staining for c-Fos. All i.p. injections are given 1 h before the start of the dark cycle. For i.c.v. injection, mice are anesthetized with metofane and given 3 μl of RPMI medium 1640 (control) or C75 in RPMI medium 1640 into the lateral ventricle with a calibrated 10-μl Hamilton syringe^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (278 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Rae C, et al. Inhibition of Fatty Acid Synthase Sensitizes Prostate Cancer Cells to Radiotherapy. [Content Brief]

[2]. Makowski K, et al. Differential pharmacologic properties of the two C75 enantiomers: (+)-C75 is a strong anorectic drug; (-)-C75 has antitumor activity. Chirality. 2013 May;25(5):281-7. [Content Brief]

[3]. Gao S, et al. Effect of the anorectic fatty acid synthase inhibitor C75 on neuronal activity in the hypothalamus and brainstem. Proc Natl Acad Sci U S A. 2003 May 13;100(10):5628-33. [Content Brief]

[4]. Thupari JN, et al. C75 increases peripheral energy utilization and fatty acid oxidation in diet-induced obesity. Proc Natl Acad Sci U S A. 2002 Jul 9;99(14):9498-502. [Content Brief]

[5]. Yan Xue, et al. Inhibition of Carnitine Palmitoyltransferase 1A Aggravates Fatty Liver Graft Injury via Promoting Mitochondrial Permeability Transition. Transplantation. 2021 Mar 1;105(3):550-560. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.9321 mL	19.6603 mL	39.3205 mL	98.3013 mL
	5 mM	0.7864 mL	3.9321 mL	7.8641 mL	19.6603 mL
	10 mM	0.3932 mL	1.9660 mL	3.9321 mL	9.8301 mL
	15 mM	0.2621 mL	1.3107 mL	2.6214 mL	6.5534 mL
	20 mM	0.1966 mL	0.9830 mL	1.9660 mL	4.9151 mL
	25 mM	0.1573 mL	0.7864 mL	1.5728 mL	3.9321 mL
	30 mM	0.1311 mL	0.6553 mL	1.3107 mL	3.2767 mL
	40 mM	0.0983 mL	0.4915 mL	0.9830 mL	2.4575 mL
	50 mM	0.0786 mL	0.3932 mL	0.7864 mL	1.9660 mL
	60 mM	0.0655 mL	0.3277 mL	0.6553 mL	1.6384 mL
	80 mM	0.0492 mL	0.2458 mL	0.4915 mL	1.2288 mL
	100 mM	0.0393 mL	0.1966 mL	0.3932 mL	0.9830 mL

Keywords

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

C75

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Anti-Breast Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Lipid Metabolism Compound Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Heterocyclic Compound Library

Metabolic Enzyme Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) C75

Biologische Aktivität

Chemical Information

Publications (52)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

C75

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Anti-Breast Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Lipid Metabolism Compound Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Heterocyclic Compound Library

Metabolic Enzyme Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) C75

Biologische Aktivität

Chemical Information

Publications (52)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

C75 Related Classifications

HY-12364 Related Classifications